Peggy Sotiropoulou
Chief Scientific Officer T-knife Therapeutics
Dr. Peggy Sotiropoulou brings 20 years of experience in oncology and immune-oncology in the biotech industry and Academia. Peggy joined T-knife from Celyad Oncology, a clinical-stage biotechnology company focused on the discovery and development of CAR-T cell therapies for cancer, where she most recently served as Head of Research & Development, leading the development of multiple autologous and allogeneic CAR-T cell candidates and non-gene edited allogeneic T cell platforms.
Seminars
As solid tumors continue to present challenges such as heterogeneity, immune evasion, and poor durability, the field is increasingly turning to advanced engineering solutions to redefine therapeutic potential. This workshop will explore cutting-edge approaches, from multi-antigen targeting strategies to next-generation TCR formats designed to amplify potency, mitigate tumor escape, and deliver deeper more durable responses that improve both patient outcomes and commercial viability.
Join this workshop to:
- Develop multi-target strategies that reduce tumor escape and expand therapeutic reach across diverse solid tumor indications
- Explore the engineering of next-generation constructs that maximize potency while maintaining safety and an optimal patient experience
- Establish best practices for monitoring cell persistence using advanced bioanalytical assays
- Assess half-life profiles to overcome dosing challenges while minimizing patient burden
- Identifying pivotal learnings that can sharpen development strategies and accelerate stronger clinical outcomes
- Framing actionable insights that translate early proof-of-concept gains into durable, real-world clinical impact
- Exploring critical knowledge gaps and defining high-value priorities that can shape the next-generation of TCR innovations
